Pharmaceuticals #semaglutide#excess stock
Semaglutide therapy market faces Rs 100 crore excess stock after initial rush
The Indian semaglutide therapy market is facing an excess stock of approximately Rs 100 crore, with stockists holding 50-60 days of inventory after a sharp slowdown in May sales. The market had surged following patent expiry in March but growth slowed drastically, leading to a halt in fresh procurement from pharmaceutical companies.
Jun 22, 2026 1 source